Abstract
The severe asthma phenotype is exhibited by a subset of asthma patients whose asthma symptom is poorly controlled by current therapies. Severe asthma represents a high unmet medical need and warrants research into the mechanisms driving the underlying pathophysiology. It is hypothesized that the underlying pathology associated with severe asthma is driving the symptoms experienced by these patients, which may share common features with mild to moderate asthma or may represent a unique pathological phenotype. For the purpose of this review, the pathophysiology associated with asthma in general are described and extended to incorporate severe asthma. Chemokines may contribute towards multiple features of asthma pathophysiology and this current review focuses on the biology of chemokines pertaining to asthma pathophysiology. Chemokines are important recruiters and activators of inflammatory cells and these infiltrating cells interact with resident cells, such as fibroblasts and it is through these pathways that chemokines appear to exert multiple biological actions. Clinical trials are underway with therapeutics targeting chemokine pathways for other inflammatory diseases. It is hoped that the information generated from these studies will contribute towards furthering our understanding of chemokine biology and be applied towards targeting severe asthma.
Keywords: Severe asthma, chemokine, inflammation, airway remodeling
Current Drug Targets
Title: Role of Chemokines in Severe Asthma
Volume: 7 Issue: 5
Author(s): L. A. Murray, F. Syed, L. Li, D. E. Griswold and A. M. Das
Affiliation:
Keywords: Severe asthma, chemokine, inflammation, airway remodeling
Abstract: The severe asthma phenotype is exhibited by a subset of asthma patients whose asthma symptom is poorly controlled by current therapies. Severe asthma represents a high unmet medical need and warrants research into the mechanisms driving the underlying pathophysiology. It is hypothesized that the underlying pathology associated with severe asthma is driving the symptoms experienced by these patients, which may share common features with mild to moderate asthma or may represent a unique pathological phenotype. For the purpose of this review, the pathophysiology associated with asthma in general are described and extended to incorporate severe asthma. Chemokines may contribute towards multiple features of asthma pathophysiology and this current review focuses on the biology of chemokines pertaining to asthma pathophysiology. Chemokines are important recruiters and activators of inflammatory cells and these infiltrating cells interact with resident cells, such as fibroblasts and it is through these pathways that chemokines appear to exert multiple biological actions. Clinical trials are underway with therapeutics targeting chemokine pathways for other inflammatory diseases. It is hoped that the information generated from these studies will contribute towards furthering our understanding of chemokine biology and be applied towards targeting severe asthma.
Export Options
About this article
Cite this article as:
Murray A. L., Syed F., Li L., Griswold E. D. and Das M. A., Role of Chemokines in Severe Asthma, Current Drug Targets 2006; 7 (5) . https://dx.doi.org/10.2174/138945006776818674
DOI https://dx.doi.org/10.2174/138945006776818674 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index to Volume 4
Current Topics in Medicinal Chemistry Arginine Kinase: A Potential Pharmacological Target in Trypanosomiasis
Infectious Disorders - Drug Targets Why is the Incidence of Type 1 Diabetes Increasing?
Current Diabetes Reviews Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Phenotyping of Chronic Obstructive Pulmonary Disease: Current Approaches and Future Directions
Current Respiratory Medicine Reviews Anti-Viral
Current Bioactive Compounds Bridging Indigenous Knowledge and Scientific Evidence for Pharmacological Studies of <i>Phaleria macrocarpa</i>: A Systematic Review
The Natural Products Journal Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets The Impact of Pharmaceutical Care Practice on the Practitioner and the Patient in the Ambulatory Practice Setting: Twenty-five Years of Experience
Current Pharmaceutical Design Novel Therapeutic Strategies for Fibrotic Lung Disease: A Review with a Focus on Epithelial-Mesenchymal Transition
Recent Patents on Inflammation & Allergy Drug Discovery Computational Analysis of Interactions of Argadin with Chitotriosidase, Chitinase and Acidic Mammalian Chitinase: Hints for Specific Inhibitor Design
Letters in Drug Design & Discovery Subclinical Hypothyroidism in Patients with Diabetic Retinopathy: Role of Vascular Endothelial Growth Factor
Endocrine, Metabolic & Immune Disorders - Drug Targets Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?
Current Drug Targets Anti-Inflammatory Mechanisms of Glucocorticoids Targeting Granulocytes
Current Drug Targets - Inflammation & Allergy Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
Current Medicinal Chemistry Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Assembly of Quinoline, Triazole and Oxime Ether in a Single Molecular Entity: A Greener and One-pot Synthesis of Novel Oximes as Potential Cytotoxic Agents
Letters in Drug Design & Discovery